MAXCYTE, INC. — Form 8-K
Filed November 10, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 72/100
What the filing says
MaxCyte (MXCT, $231M market cap) is acquiring Ohio Intermediate LLC and related entities (collectively 'Acquired Companies,' primarily BioP) from Ohio TopCo LP and Arcline Capital Partners for: (1) Estimated Closing Cash Payment (subject to working capital adjustment), (2) Stock Consideration (unspecified share count, <20% of MaxCyte), and (3) $20M in Deferred Payments ($10M each in 2028 and 2029). Transaction dated November 9, 2026, with Closing expected ~120 days thereafter pending HSR clearance. Deal includes $10M-$20M earnout-like deferred components and assumes Acquired Companies' indebtedness and transaction expenses.
Why this rating
Material acquisition funded by mix of cash/stock/deferred payments; deal scale relative to $231M market cap material but not transformational; execution risk on HSR approval and working capital finalization; non-compete/standstill terms protect sellers' stock position.
Price action (we called it neutral)
before filing · preread $1.35 ▼ 3.20% | at our read · unknown $1.40 | +10 min · unknown $1.39 ▼ 0.36% | +30 min · unknown $1.38 ▼ 1.08% | +1 hr · unknown $1.26 ▼ 9.68% | +4 hrs · unknown $1.13 ▼ 19.00% |
The stock had already moved +3.31% between hitting EDGAR and our read finishing — deltas above are measured from our read.
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from November 10, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.